A study of the effects of sumatriptan on myocardial perfusion in healthy female migraineurs using 13NH3 positron emission tomography

Neurology

Volumn 48, Issue 6, 1997, Pages 1542-1550

  Lewis, P J ^a,c   Barrington, S F ^a   Marsden, P K ^a   Maisey, M N ^a   Lewis, L D ^b  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY HOSPITAL LEWISHAM   (United Kingdom)

^c DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SEROTONIN 1 AGONIST; SEROTONIN 1D RECEPTOR; SUMATRIPTAN;

ADULT; ANAMNESIS; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; ELECTROCARDIOGRAM; FEMALE; HEART MUSCLE PERFUSION; HUMAN; MIGRAINE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; THORAX PAIN;

EID: 0030822780     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.48.6.1542     Document Type: Article

References (29)

1. The Subcutaneous Sumatriptan International Study Group Treatment of migraine attacks with sumatriptan. N Engl J Med 1991;325:316-321.
2. Cady RK, Wendt JK, Kirchner JR, Sargent JD, Rothrock JFSJ. Treatment of acute migraine with subcutaneous sumatriptan. JAMA 1991;265:2831-2835.
3. Brown EG, Endersby CA, Smith RN, Talbot JCC. The safety and tolerability of sumatriptan: an overview. Eur Neurol 1991;31:339-344.
4. Willett F, Curzen N, Adams J, Armitage M. Coronary vasospasm induced by subcutaneous sumatriptan [letter]. BMJ 1992;305:117-118.
5. Stricker BHC. Coronary vasospasm and sumatriptan [letter]. BMJ 1992;305:117-118.
6. Inman W, Kubota K. Cardiorespiratory distress after sumatriptan given by injection. BMJ 1992;305:714.
7. Ottervanger JP, Paalman HJA, Boxma GL, Strickler BHC. Transmural myocardial infarction and sumatriptan. Lancet 1993;341:861-862.
8. Kelly KM. Cardiac arrest following use of sumatriptan. Neurology 1995;45:1211-1213.
9. Ottervanger JP, van Witsen TB, Valkenburg HA, Grobbee DE, Strickler BHC. Adverse reactions attributed to sumatriptan. A postmarketing study in general practice. Eur J Clin Pharmacol 1994;47:305-309.
10. 2 receptor activation. Eur J Pharmacol 1989;161:91-94.
11. 1-like receptors. Arch Pharmacol 1992;346:592-596.
12. Cushing DJ, Cohen ML. Serotonin-induced relaxation in canine coronary artery smooth muscle. J Pharmacol Exp Ther 1992;263:123-129.
13. Bax WA, Renzenbrink GJ, Van Heuven-Nolsen D, Thijssen EJM, Bos E, Saxena P. 5-HT receptors mediating contractions of the isolated human coronary artery. Eur J Pharmacol 1993; 239:203-210.
14. Ginsburg R, Bristow MR, Davis K, Dibiase A, Billingham ME. Quantitative pharmacological responses on normal and atherosclerotic isolated human epicardial coronary arteries. Circulation 1984;69:430-440.
15. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalgia 1988;8(suppl 7):19-28.
16. Fowler PA, Lacey LF, Thomas M, Keene ON, Tanner RJN, Baber NS. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur Neurol 1991;31:291-294.
17. Muzik O, Beanlands RSB, Hutchins GD, Mangner TJ, Nguyen N, Schwaiger M. Validation of nitrogen-13-ammonia tracer kinetic model for quantification of myocardial blood flow using PET. J Nucl Med 1993;34:83-91.
18. Choi Y, Huang S, Hawkins RA, et al. A simplified method for quantification of myocardial blood flow using nitrogen-13-ammonia and dynamic PET. J Nucl Med 1993;34:488-497.
19. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 1985;5:584-590.
20. Raylman RR, Caraher JM, Hutchins GD. Sampling requirements for dynamic cardiac PET studies using image-derived input functions. J Nucl Med 1993;34:440-447.
21. Andrew PD, Birch HL, Phillpot DA. Determination of sumatriptan succinate in plasma and urine by high-performance liquid chromatography with electrochemical detection. J Pharm Sci 1993;82:73-76.
22. Houghton LA, Foster JM, Whorwell PJ, Morris J, Fowler P. Is chest pain after sumatriptan oesphageal in origin? Lancet 1994;344:985-986.
23. 1 agonist, on the systemic, pulmonary and coronary circulation. Circulation 1993;87:401-405.
24. MacIntyre PD, Bhargava B, Hogg KJ, Gemmill JD, Hillis WS. The effect of i.v. sumatriptan, a selective 5-HT1-receptor agonist on central haemodynamics and the coronary circulation. Br J Clin Pharmacol 1992;34:541-546.
25. Golino P, Piscione F, Willerson JT, et al. Divergent effects of serotonin on coronary-artery dimensions and blood flow in patients with coronary artherosclerosis and control patients. N Engl J Med 1991;324:641-648.
26. MacLean MR, Smith GCS, Templeton AGB. Adverse reactions associated with sumatriptan. Lancet 1993;341:1092.
27. McFadden EP, Clarke JG, Davies GJ, Kaski JC, Haider AW, Maseri A. Effect of intracoronary serotonin on coronary vessels in patients with stable angina and patients with variant angina. N Engl J Med 1991;324:648-654.
28. Palmer J, Feldman R, Mancini GBJ, Zimmerman M. Glyceryl trinitrate reversal of post-sumatriptan coronary artery narrowing. Lancet 1995;345:1366.
29. Gistri R, Cecchi F, Choudry L, et al. Effect of verapamil on absolute myocardial blood flow in hypertrophic cardiomyopathy. Am J Cardiol 1994;74:363-368.